Barinthus Biotherapeutics plc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
License revenue
Service revenue
Research grants and contracts
Total revenue

Operating expenses
Research and development
General and administrative
Impairment of intangible assets
Goodwill impairment
Total operating expenses
Other operating income
Loss from operations
Other income/(expense):
Change in fair value of derivatives embedded in convertible loan notes
Unrealized foreign exchange gain on convertible loan notes
Loss on extinguishment of convertible loan notes
Interest income
Interest expense
Research and development incentives
Other income
Total other income, net

Loss before income tax
Tax benefit
Net loss
Other comprehensive gain/(loss) – foreign currency translation adjustments
Comprehensive loss
Comprehensive loss/(gain) attributable to noncontrolling interest
Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders
Net loss attributable to noncontrolling interest
Net loss attributable to Barinthus Biotherapeutics plc shareholders
Weighted-average ordinary shares outstanding, basic (in shares)
Weighted-average ordinary shares outstanding, diluted (in shares)
Net loss per share attributable to ordinary shareholders, basic (in usd per share)
Net loss per share attributable to ordinary shareholders, diluted (in usd per share)

Comments